



# CBD 2020

## CONFERENCE

A Special  
Pre-Conference  
Event

Exploring the Evidence for Medical Cannabis in Clinical Practice

# 12TH ANNUAL

## CHAIR SUMMIT

Master Class for Neuroscience Professional Development

Pre-Conference – Feb. 26-27, 2020 | Main Conference – Feb. 27-29, 2020 | The LINQ

#CBD2020  
#CHAIR2020  
@cmeoutfitters

Provided by 

**TABLE OF CONTENTS**

**CBD 2020 Conference Information ..... 2-7**

- Accreditation ..... 2
- Agenda ..... 3-4
- Faculty Information..... 5-7

**12th Annual Chair Summit Information ..... 8-9**

- B.Y.O.D. Technology Instructions..... 8
- Instructions for Evaluations, Obtaining Credit, and Presentation Slides .. 8
- Wi-Fi Access Code ..... 8
- Meeting Details and Accreditation Information..... 9

Agenda ..... 10-13

Faculty Information..... 14-19

- Presenting Faculty Titles and Affiliations ..... 14
- Faculty Bios..... 15-19
- Disclosure Declaration ..... 20-21

Twitter Guide ..... 22

Notes Pages ..... 23-27

Hotel Floor Plan..... 28

**ACKNOWLEDGEMENTS**

*Funding for this certified CME/CE activity is provided by educational grants as listed below.*

*The insomnia sessions are supported by an educational grant from Eisai Inc.*

*The MS sessions are supported by an educational grant from Celgene Corporation.*

*The OUD sessions are supported by an educational grant from Alkermes, Inc.*

*The spasticity sessions are supported by an educational grant from Allergan.*

# CBD 2020 A Special Pre-Conference Event

# CONFERENCE

Exploring the Evidence for Medical Cannabis in Clinical Practice

## OVERVIEW

Health care professionals (HCPs) are seeing an increased number of patients asking for evidence-based information about medical cannabis and the potential use of cannabis and CBD for a myriad of disorders, but often feel ill-equipped to provide sound advice about its use. Differences between cannabis products used in clinical trials compared to what is available to patients in the market add complexity to the conversation, making it difficult for clinicians to make informed decisions and counsel patients. Concerns about drug-drug interactions between medical cannabis and other medical therapies contribute even more uncertainty.

To provide you with the evidence-based guidance needed to confidently provide your patients with the information they seek, **CME Outfitters presents CBD Conference 2020: Exploring the Evidence for Medical Cannabis in Clinical Practice.**

## CE CREDIT INFORMATION

**CME Credit (Physicians):** CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC designates this live activity for a maximum of 7 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Physician Assistants:** The AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credits™* from organizations accredited by the Accreditation Council for Continuing Medical Education.

**ABPN MOC:** ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

**ABIM MOC:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is CME Outfitters' responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC Credit.

**CNE Credit (Nurses):** Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 7 contact hours.

**Nurse Practitioners:** NPs can apply for *AMA PRA Category 1 credit™* through the American Academy of Nurse Practitioners (AANP). AANP will accept *AMA PRA Category 1 credit™* from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

**CPE Credit (Pharmacists):** CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 7 contact hours (7 CEUs)



Universal Activity Number: Live: 0376-0000-20-005-L01-P  
Type: knowledge-based

## MIPS IMPROVEMENT ACTIVITY



IMPROVEMENT ACTIVITY

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

## CREDIT REQUEST



Please visit [www.chairsummit.com/CBDcredit](http://www.chairsummit.com/CBDcredit) once you return home and claim your credits. You will be able to print your certificate immediately.

## PRESENTATION SLIDES



Presentation slides will be available for download at [www.chairsummit.com/CBD2020resources](http://www.chairsummit.com/CBD2020resources)

## WEDNESDAY, FEBRUARY 26TH: 11:00 AM – 5:30 PM

- 11:00 – 1:00      **REGISTRATION / CHECK-IN**
- 1:00 – 1:15      **WELCOME TO THE CBD 2020 CONFERENCE**  
*Paul R. Carney, MD*
- 1:15 – 1:45      Therapeutic Uses of Medical Cannabis  
*Kevin P. Hill, MD, MHS*
- 1:45 – 2:15      When Parents Ask About CBD and Autism Spectrum Disorder:  
Evidence or Anecdotal?  
*Gregory N. Barnes, MD, PhD*
- 2:15 – 2:45      CBD for Chronic Pain Management  
*Michael Saulino, MD, PhD*
- 2:45 – 3:15      **OPEN DISCUSSION Q&A / PANEL DISCUSSION**  
*Moderated by Paul R. Carney, MD*
- 3:15 – 3:45      **BREAK**
- 3:45 – 4:15      Practical Considerations in Creating a Medical Cannabis  
Practice  
*Michael Saulino, MD, PhD*
- 4:15 – 4:45      The Evidence Supporting CBD Use in Rare Neurologic  
Behavioral Disorders  
*Paul R. Carney, MD*
- 4:45 – 5:30      **OPEN DISCUSSION Q&A / PANEL DISCUSSION**  
*Moderated by Paul R. Carney, MD*

## THURSDAY, FEBRUARY 27TH: 8:00 AM – 11:30 AM

8:00 – 9:00	<b>BREAKFAST</b>
8:30 – 9:00	<b>OPEN DISCUSSION Q&amp;A</b> <i>Moderated by Paul R. Carney, MD</i>
9:00 – 9:30	HIV infection: A Model for the Use of Cannabinoid-based Anti-inflammatory Agents <i>John W. Sleasman, MD</i>
9:30 – 10:00	Insomnia and Sleep Disorders <i>Jordan Tishler, MD</i>
10:00 – 10:30	<b>BREAK</b>
10:30 – 11:00	Talking with Patients to Reach an Informed Decision Together <i>David Grelotti, MD</i>
11:00 – 11:30	<b>OPEN DISCUSSION Q&amp;A / PANEL DISCUSSION</b> <i>Moderated by Paul R. Carney, MD</i>
11:30	<b>ADJOURNMENT OF THE CBD 2020 CONFERENCE</b>

## DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporters of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Evan Luburger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

## PRESENTING FACULTY FOR THE CBD 2020 CONFERENCE

### **Paul R. Carney, MD (Chairman)**

Professor of Neurology, Pediatrics, and Neuroscience  
University of North Carolina at Chapel Hill  
Chapel Hill, NC

*Disclosures: No disclosures to report*

### **Gregory N. Barnes, MD, PhD**

Spafford Ackerly Chair for Child and Adolescent  
Psychiatry  
Professor of Neurology and Pediatrics  
Director, University of Louisville Autism Center  
Department of Neurology  
University of Louisville School of Medicine  
Louisville, KY

*Disclosures: Grants: GW Pharmaceutical/Greenwich  
Biosciences, Inc. (Clinical trial grant entitled: The Role  
of Cannabinoid Signaling in Autism and Epilepsy)*

### **Mark S. Gold, MD**

ASAM's Annual Lifetime Achievement  
John P. McGovern Award & Prize Winner  
Adjunct Professor of Psychiatry  
Washington University School of Medicine  
St. Louis, MO  
17th University of Florida Distinguished Alumni  
Professor  
Gainesville, FL

*Disclosures: See page 20*

### **David Grelotti, MD**

Medical Director  
University of California Center for Medicinal  
Cannabis Research (CMCR)  
Associate Professor of Psychiatry  
University of California San Diego School of Medicine  
San Diego, CA

*Disclosures: Consultant: Cannabis Educators Working  
Group funded by Greenwich Biosciences, Inc.*

### **Kevin P. Hill, MD, MHS**

Director, Division of Addiction Psychiatry  
Beth Israel Deaconess Medical Center  
Associate Professor of Psychiatry  
Harvard Medical School  
Boston, MA

*Disclosures: Research/Grants: National Institute of  
Drug Addiction (NIDA), World Health Organization;  
Other financial or material support: Hazelden and  
Wolters Kluwer*

### **Michael Saulino, MD, PhD**

Physiatrist  
MossRehab  
Associate Professor  
Department of Rehabilitation Medicine  
Thomas Jefferson University  
Philadelphia, PA

*Disclosures: Research Support: Bioness Inc.;  
Medtronic; and TerSera Therapeutics LLC; Speakers  
Bureau: Ipsen Biopharmaceuticals, Inc.; Medtronic;  
and TerSera Therapeutics LLC*

### **John W. Sleasman, MD**

Dr. Glenn A. Kiser and Eltha Muriel Kiser Professor of  
Pediatrics  
Chief, Division of Allergy, Immunology, and Pulmonary  
Medicine  
Department of Pediatrics  
Duke University School of Medicine  
Durham, NC

*Disclosures: Grants: 1U01-DA044571-02 NIH/NIDA  
Consequences of marijuana use on inflammatory  
pathways in HIV-infected youth*

### **Jordan Tishler, MD**

Harvard Medical School  
President, Association of Cannabis Specialists  
President and CMO, InhaleMD  
Boston, MA

*Disclosures: No disclosures to report*



## FACULTY BIOS

### **Paul R. Carney, MD (Chairman)**

Dr. Carney is Professor of Neurology, Pediatrics, and Neuroscience at the University of North Carolina at Chapel Hill. Dr. Carney is an internationally recognized expert in the diagnosis and treatment of individuals with epilepsy and other chronic neurological disorders. He has authored more than 350 articles, abstracts, books, and book chapters. His research is frequently featured in the national and international press, including MSNBC and the New York Times, and in interviews and features on ABC, NBC, and the Discovery channel. Dr. Carney led the first state-supported program to test the effectiveness and safety of cannabidiol for individuals with epilepsy and behavioral problems. His translational research group is studying the disease-modifying effects of phytocannabinoids on drug addiction, Alzheimer's disease, autism, and Angelman syndrome, among other disorders.

### **Gregory N. Barnes, MD, PhD**

Dr. Barnes is the inaugural permanent director of the University of Louisville (UL) Autism Center. Dr. Barnes also holds the Spafford Ackerly Chair for Child and Adolescent Psychiatry and is a tenured professor in the Departments of Neurology and Pediatrics. His research focuses on potential genetic influences into the development of ASD and epilepsy and how these factors contribute to outcomes and potential new treatments. Dr. Barnes, UL Professor of Neurology and Pediatrics, has held academic appointments at Washington University School of Medicine in St. Louis, Harvard Medical School, Duke University Medical School, the University of Kentucky College of Medicine, and Vanderbilt School of Medicine. He has authored or co-authored 58 research articles/book chapters in the fields of neurology, autism, and epilepsy. He now serves as PI of several national multi-site grants to understand the role of cannabinoid signaling in autism.

### **Mark S. Gold, MD**

See page 15

### **David Grelotti, MD**

Dr. Grelotti is an Associate Professor of Psychiatry at the University of California San Diego and the Medical Director of the University of California Center for Medicinal Cannabis Research (CMCR). An adult and child psychiatrist, he graduated from medical school at the Johns Hopkins University School of Medicine and completed residency training at Harvard Medical School. With colleagues at the CMCR, he is conducting a study of cannabis-related driving impairment, a randomized, placebo-controlled clinical trial of cannabis for low back pain, and investigations of the impact of cannabinoids on the endocannabinoid system in bipolar disorder, HIV, and healthy persons. His research is funded by the National Institutes of Health and the State of California.

### **Kevin P. Hill, MD, MHS**

Dr. Hill is Director of Addiction Psychiatry at Beth Israel Deaconess Medical Center (BIDMC) and an Associate Professor of Psychiatry at Harvard Medical School. He earned a Master's in Health Science at the Robert Wood Johnson Clinical Scholars Program at the Yale School of Medicine. He most commonly treats patients who have problems with alcohol, cannabis, or opioids and has been named one of Boston Magazine's Top Doctors for the past 2 years. He treats professional athletes from the National Football League (NFL), the National Basketball Association, and the Boston Red Sox, as well as airline pilots. He consults for the NFL and is the Co-Chair of the NFL/NFL Players Association Pain Management Committee. The author of *Marijuana: The Unbiased Truth about the World's Most Popular Weed (Hazelden 2015)* and co-author of *Medical Cannabis: An Evidence-Based Guide (Wolters-Kluwer 2020)*, Dr. Hill's research interests include the development of medications to treat cannabis use disorder as well as cannabis policy, and he has published widely on these topics in such journals as *JAMA*, *JAMA Internal Medicine*, and *Lancet Psychiatry*. In 2018, he was awarded a grant to summarize the research on the therapeutic use of cannabis, and he presented his findings to the World Health Organization's Expert Committee on Drug Dependence in Geneva, Switzerland. He serves on the editorial boards of *Lancet Psychiatry*, *Cannabis and Cannabinoid Research*, and *American Journal on Addictions*.

Dr. Hill has become an internationally recognized speaker on addiction topics due to his ability to connect with audiences and make complex concepts understandable. He gives balanced, evidence-based talks on cannabis, opioids, and alcohol to a wide variety of audiences.

### **Michael Saulino, MD, PhD**

Dr. Saulino, a physiatrist at MossRehab, is board certified in Physical Medicine and Rehabilitation, Spinal Cord Injury Medicine, and Pain Management. He earned his PhD (Biological Chemistry) and MD degrees from the Pennsylvania State University College of Medicine in 1993. He completed residency training in Physical Medicine and Rehabilitation at Thomas Jefferson University in 1997 and was chief resident in his final year of residency training. Dr. Saulino is an associate professor in the Department of Rehabilitation Medicine at both the Sidney Kimmel Medical College and Temple University College of Medicine. He was recently honored by the American Academy of Physical Medicine and Rehabilitation with the 2018 Distinguished Clinician Award.

Dr. Saulino's areas of clinical and research interest include pain management, spasticity management, neuromodulation, peripheral nerve stimulation, and intrathecal therapy. A number of patient populations are served by these techniques including spinal cord injury, stroke, brain injury, cerebral palsy, multiple sclerosis, and chronic pain. He also manages the Eastern Regional clinic for adults with spina bifida.

Dr. Saulino has published a number of scientific articles in prestigious medical journals including the *PM&R*, *Archives of Physical Medicine and Rehabilitation*, *American Journal of Physical Medicine and Rehabilitation*, *Neurorehabilitation and Neural Repair*, *Neurology*, *Spinal Cord*, and *Neuromodulation*. He is also a reviewer and associate editor for *Neuromodulation*.

### **John W. Sleasman, MD**

Dr. Sleasman is the Dr. Glenn A. Kiser and Eltha Muriel Kiser Professor of Pediatrics and Chief of the Division of Allergy, Immunology, and Pulmonary Medicine at Duke University where he is also Co-Director of the Duke Diagnostic Immunology Laboratory and Medical Director the Duke's Jeffrey Modell Diagnostic and Research Center for Primary Immune Deficiencies Diseases. Prior to moving to Duke in 2013, he held Robert A. Good Endowed Chair in Immunology at the University of South Florida. Over the past 25 years, Dr. Sleasman's research has focused on HIV pathogenesis and treatment in infants, children, and adolescents. He has over 130 peer-reviewed publications, books, and book chapters, most relating to basic and clinical research to HIV pathogenesis and treatment. His studies have helped determine how antiretroviral therapy prevents maternal-to-child transmission and have described how effective antiretroviral therapy reconstitutes immunity in HIV-infected children. More recently, his research team is examining the implications of HIV-induced macrophage activation in HIV pathogenesis.

In the past, Dr. Sleasman has been a member of the Florida Medical Association's special committee on HIV/AIDS, has served on the Scientific Advisory board of the Elizabeth Glaser Pediatric AIDS Foundation, and was Chairperson of the Adolescent Research Agenda Committee for the Pediatric AIDS Clinical Trial Group. He is a former chairperson of the Therapeutic Leadership Group for the NICHD Adolescent Trials Network. Dr. Sleasman has served as Chairman of the AIDS Immunology and Pathogenesis Study Section, Center for Scientific Review, and National Institutes of Health and is currently a member of the Executive Scientific Leadership Committee of the International Maternal, Pediatric, Adolescent, AIDS Clinical Trial Group. Among his honors, he provided invited testimony before the United States Congress, Subcommittee on Commerce, regarding the re-authorization of the Ryan White C.A.R.E. Act. As a result of his research, he received the University of Florida Clinical Science Faculty Research Award and the *Silver Award for Pediatric AIDS Research* by Children's Hospital of Philadelphia.

### **Jordan Tishler, MD**

Dr. Tishler is a cannabis specialist. Through his training in internal medicine and years of practice as an emergency physician, Dr. Tishler brings his knowledge, reason, and caring to patients at InhaleMD, and through his advocacy work at the local and national levels.

Dr. Tishler graduated from both Harvard College and Harvard Medical School, trained at the Brigham and Women's Hospital, and is faculty at both the Brigham and Women's Hospital and Harvard Medical School. He has spent many years working with the underserved, particularly providing care for veterans. Having treated countless patients harmed by alcohol and drugs, his observation that he had never seen a cannabis overdose led Dr. Tishler to delve deeply into the science of cannabis safety and treatment.

Dr. Tishler is a frequent speaker and author on a variety of topics related to the medical applications of cannabis. He is the President of the Association of Cannabis Specialists, which aims to educate clinicians, lawmakers, and the industry about best practices and needed tools for proper patient care.



# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development



## INSTRUCTIONS FOR OUR INTERACTIVE TECHNOLOGY

If you would like to use your own tablet or mobile device to answer polling questions, or if you're using one of our iPads to view the onsite presentations, and submit questions to the faculty, please follow the instructions below:

### 1. Get Connected

- Please connect to the **CME Outfitters** network with your mobile device or laptop. This network does not have a password. **Please note that this network is a local network and does not mean you're connected to the internet.**
- Once you have joined the network, go to **arraylearn.com**
- You will be required to provide your email. Please enter your **email address**, and click submit.
- You are now connected to the conference. All content and polling questions can be viewed on your device as long as you are connected to the above listed network.

### 2. Ask a Question to the Faculty

- Please click on "**Submit a Faculty Question**" and type your question. Please include the faculty member's name if the question is specifically for them. Your question will be sent to the faculty for the question and answer portion of the session.

### 3. View and Take Notes on Presentation Slides

- Please click on the "**Take a Note on This Slide**" button. When the meeting is complete, all your notes will be emailed to you within 5 business days.

## EVALUATIONS AND CREDIT REQUEST

Plenary session evaluations will be automatically available on the iPads at the end of each session during Q&A. Breakout session evaluations will be automatically available on the iPads following each designed breakout block in the agenda.



Please visit **www.chairsummit.com/credit** once you return home and claim your credits. You will be able to print your certificate immediately.

## EMAIL ADDRESS

Your e-mail address is required and will be used for the daily evaluations link, outcomes, educational research, and certification. **We will never exchange, sell, or rent your e-mail to any third-party for commercial purpose.**

## PRESENTATION SLIDES



Presentation slides will be available for download at **www.cmeoutfitters.com/2020resources**

## WI-FI ACCESS\*

Connect to the internet via hotel wi-fi using hotel network: **CME Outfitters** and password: **lasvegas2020**

*\* Please keep in mind that when you are connected to the symposium network the wireless internet access is no longer available, which helps ensure the highest quality tablet experience.*

## LEARNING OBJECTIVES

At the end of this CME/CE conference, participants should be able to:

- Integrate evidence-based best care into everyday clinical practice, including the latest measurement- and outcomes-based clinical research and data on psychiatric and neurologic disorders.
- Translate current and emerging scientific evidence into clinical practice and individualized care decisions for psychiatric and neurologic disorders.
- Actively participate in open, unfiltered discussions with experts, interdisciplinary team members, and colleagues regarding the challenges in daily clinical practice so that new insights can be applied to improve patient care.

The following learning objectives pertain only to those requesting CNE/CPE credit:

- Identify validated questionnaires used to assess symptoms of psychiatric and neurologic disorders.
- Describe best practices for diagnosis and treatment of psychiatric and neurologic disorders based on review of high-level evidence and discussions with clinical experts and colleagues.

## TARGET AUDIENCE

Physicians, physician assistants, nurses, nurse practitioners, pharmacists, and other non-physician health care professionals with an interest in psychiatry, neurology, and the neurosciences.

### CE CREDIT INFORMATION

**CME Credit (Physicians):** CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Physician Assistants:** The AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

**ABPN MOC:** ABPN Diplomates may select any CME activity relevant to their practice to count towards ABPN MOC requirements.

**ABIM MOC:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is CME Outfitters' responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC Credit.

**CNE Credit (Nurses):** Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 16.25 contact hours.

**Nurse Practitioners:** NPs can apply for AMA PRA Category 1 credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

**CPE Credit (Pharmacists):** CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 16.25 contact hours (1.825 CEUs)

Universal Program Number: 0376-0000-20-004-L01-P  
Activity Type: Knowledge-based

### MIPS IMPROVEMENT ACTIVITY

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA\_PSPA\_28) for the Merit-based Incentive Payment Program (MIPS). Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.



# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

## AT-A-GLANCE LOCATIONS

**All Plenary Sessions:** Social A (3rd Floor)

**Exhibit / Meals:** Social B & C (3rd Floor)

**Breakout & Chart Review Sessions:** Noted in the Agenda Below (3rd & 4th Floor)

*Hotel floor plan on page 28 for reference*

## THURSDAY, FEBRUARY 27TH: 11:45 AM – 6:00 PM

- 11:45 – 1:00      **REGISTRATION / CHECK-IN**
- 1:00 – 1:30      **WELCOME TO THE 12TH ANNUAL CHAIR SUMMIT**  
*Charles B. Nemeroff, MD, PhD*
- 1:30 – 2:30      Electroceuticals in Neuro/Psychiatric Disorders  
*David Paydarfar, MD*
- 2:30 – 3:30      Mental Health and Substance Use On Campus: New Solutions  
*Steven Siegel, MD, PhD*
- 3:30 – 4:00      **BREAK IN EXHIBIT HALL**
- 4:00 – 5:30      **PANEL DISCUSSION:  
BENEATH THE SURFACE OF SUICIDE**  
Progress in Suicide Prevention  
*Charles B. Nemeroff, MD, PhD*  
Suicide: Connections to Insomnia  
*W. Vaughn McCall, MD, MS*  
Suicide: Overdose Deaths of Despair  
*Mark S. Gold, MD*
- 5:30 – 6:00      **OPEN DISCUSSION Q&A / PANEL DISCUSSION**

## FRIDAY, FEBRUARY 28TH: 7:45 AM – 7:00 PM

- 7:45 – 8:15      **BREAKFAST**
- 8:15 – 9:00      Staying in Your Lane? Practical Guide to Use of Hormones in  
Everyday Practice  
*C. Neill Epperson, MD*
- 9:00 – 9:45      Advancing Precision Medicine for PTSD in Civilians and Military  
*Charles R. Marmar, MD*
- 9:45 – 10:30      Conceptualizing Novel Early Life Interventions for Anxiety  
and Depression  
*Ned H. Kalin, MD*

- 10:30 – 11:00 **BREAK IN EXHIBIT HALL**
- 11:00 – 11:45 **BREAKOUT SESSIONS (ROUND I)**
- Personalized Strategies to Optimally Manage Insomnia: Have You Been Sleeping on Best Practices?  
*W. Vaughn McCall, MD, MS*  
(Connection A)
- Technology in Medicine: New Frontiers Leading to Better Care  
*David Paydarfar, MD*  
(Connection B)
- Laboratory Testing in Psychiatry  
*Charles B. Nemeroff, MD, PhD*  
(Icon A)
- Schizophrenia: Distinguishing the Impact of Biomarkers on Patients and Populations  
*Steven Siegel, MD, PhD*  
(Icon C1)
- New Strategies for Treating PTSD in Active Duty Military and Veterans  
*Charles R. Marmar, MD*  
(Icon C2)
- Clinical Decision-Making in OUD Management: Treatment Selection and Implementation  
*Mark S. Gold, MD*  
(Icon G)
- 11:45 – 12:00 **EVALUATIONS**
- 12:00 – 12:45 **BREAKOUT SESSIONS (ROUND II)**  
(Same as Round I, See 11:00 – 11:45)
- 12:45 – 1:30 **LUNCH**
- Updates on the Management of Insomnia: Expert Guidance Through the Latest Clinical Trials on Dual Orexin Receptor Antagonists  
*W. Vaughn McCall, MD, MS*
- 1:30 – 2:15 Spasticity: Diagnosis, Assessment, Comorbidity and Management  
*David Simpson, MD*
- 2:15 – 3:00 Ketamine and Esketamine: The Amazing, The Good, The Bad, and The Ugly  
*Charles B. Nemeroff, MD, PhD*

# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

- 3:00 – 3:30 **BREAK IN EXHIBIT HALL**
- 3:30 – 4:15 **CHART REVIEW SESSIONS (ROUND I)**
- Schizophrenia  
*Steven Siegel, MD, PhD*  
*(Connection A)*
- Treatment Resistant Depression  
*Charles B. Nemeroff, MD, PhD*  
*(Connection B)*
- Anxiety  
*Ned H. Kalin, MD; Charles R. Marmar, MD*  
*(Icon A)*
- Treatment Selection for Insomnia in Elderly Patients:  
Navigating the Dos and Don'ts  
*W. Vaughn McCall, MD, MS*  
*(Icon C1)*
- Bringing Evidence-Based Strategies for OUD Management  
into Your Clinical Practice  
*Mark S. Gold, MD*  
*(Icon C2)*
- The Powerful Impact of Hormones on the Brain  
*C. Neill Epperson, MD*  
*(Icon C3)*
- 4:15 – 4:30 **OPEN DISCUSSION Q&A / EVALUATIONS**
- 4:30 – 5:15 **CHART REVIEW SESSIONS (ROUND II)**  
(Same as Round I, See 3:30 – 4:15)
- 5:15 – 5:30 **EVALUATIONS**
- 5:30 – 6:15 Curbing the Impact of the Opioid Epidemic: Arm Yourself  
with the Latest Tools and Strategies to Manage OUD  
*Mark S. Gold, MD*
- 6:15 – 7:00 **RECEPTION / CHAIR AWARD**  
*(Keys Ballroom)*

## **SATURDAY, FEBRUARY 29: 7:45 AM – 12:30 PM**

- 7:45 – 8:15     **BREAKFAST**
- 8:15 – 9:00     GABA-Enhancing Neurosteroids as New  
Treatments in Psychiatry  
*Charles F. Zorumski, MD*
- 9:00 – 9:45     Translating Evidence to Practice: Approaches for  
Individualized and Patient-Centered MS Care  
*Fred D. Lublin, MD*
- 9:45 – 10:30    Interventional Psychiatry and the Treatment of  
Refractory Depression  
*Charles F. Zorumski, MD*
- 10:30           **WRAP UP AND ADJOURNMENT OF THE  
12TH ANNUAL CHAIR SUMMIT**

### **THANK YOU FOR YOUR PARTICIPATION**

Please be on the lookout for other CME/CE opportunities you may be interested in at  
[www.CMEOutfitters.com](http://www.CMEOutfitters.com)!

### **SPECIAL THANK YOU TO OUR EXHIBITOR**

#### **Magstim, Inc.**

Magstim® is a leading supplier of Transcranial Magnetic Stimulation (TMS) stimulators and packages used for Magstim® TMS therapy and neuromodulation research.

[www.magstim.com](http://www.magstim.com)

**Learn more about Magstim, Inc. at the exhibitor booth on the 3rd Floor.**



# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

## PRESENTING FACULTY

### **Charles B. Nemeroff, MD, PhD (Chairman)**

Professor and Chair  
Department of Psychiatry  
Mulva Clinic for the Neurosciences  
Director, Institute of Early Life Adversity Research  
Dell Medical School  
The University of Texas at Austin  
Austin, TX

### **C. Neill Epperson, MD**

Robert Freedman Endowed Professor and Chair  
Department of Psychiatry  
University of Colorado School of Medicine -  
Anschutz Medical Campus  
Aurora, CO

### **Mark S. Gold, MD**

ASAM's Annual Lifetime Achievement  
John P. McGovern Award & Prize Winner  
Adjunct Professor of Psychiatry  
Washington University School of Medicine  
St. Louis, MO  
17th University of Florida Distinguished Alumni  
Professor  
Gainesville, FL

### **Ned H. Kalin, MD**

Hedberg Professor and Chairman  
Department of Psychiatry  
University of Wisconsin School of Medicine and  
Public Health--Madison  
Director, HealthEmotions Research Institute  
Madison, WI

### **Fred D. Lublin, MD**

Saunders Family Professor of Neurology  
Director, Corinne Goldsmith Dickinson Center for MS  
Icahn School of Medicine at Mount Sinai  
New York, NY

### **Charles R. Marmar, MD**

Lucius N. Littauer Professor and Chair  
Director, Center for Alcohol Use Disorder and PTSD  
Department of Psychiatry  
NYU Langone Health  
New York, NY

### **W. Vaughn McCall, MD, MS**

Case Distinguished University Chair  
Department of Psychiatry and Health Behavior  
Executive Vice Dean  
Medical College of Georgia  
Augusta University  
Augusta, GA

### **David Paydarfar, MD**

Professor and Chair  
Department of Neurology  
Dell Medical School, The University of Texas at Austin  
Austin, TX

### **Steven Siegel, MD, PhD**

Professor and Chair  
Department of Psychiatry and Behavioral Sciences  
Franz Alexander Chair in Psychiatry  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA

### **David M. Simpson, MD, FAAN**

Professor of Neurology  
Director, Clinical Neurophysiology and Neuromuscular  
Division  
Icahn School of Medicine at Mount Sinai  
New York, NY

### **Charles F. Zorumski, MD**

Samuel B. Guze Professor and Head of Psychiatry  
Professor of Neuroscience  
Director, Taylor Family Institute for Innovative  
Psychiatric Research  
Washington University School of Medicine  
St. Louis, MO

## FACULTY BIOS

### **Charles B. Nemeroff, MD, PhD (Chairman)**

Prior to joining Dell Med, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. He has served as president of the American College of Psychiatrists (ACP) and the American College of Neuropsychopharmacology (ACNP) and sits on the Scientific Advisory Board and board of directors of the American Foundation for Suicide Prevention (AFSP) and the Anxiety and Depression Association of America (ADAA).

He is a member of the APA Council on Research and chairs both the APA Research Colloquium for Young Investigators and the APA Work Group on Biomarkers and Novel Treatments.

His research is focused on the pathophysiology of mood and anxiety disorders with a focus on the role of child abuse and neglect as a major risk factor. He has also conducted research on the role of mood disorders as a risk factor for major medical disorders including heart disease, diabetes, and cancer. He has published more than 1,100 research reports and reviews, and his research is currently supported by grants from the National Institutes of Health.

He has also served on the Mental Health Advisory Council of the National Institute of Mental Health and the Biomedical Research Council for NASA; is co-editor in chief (with Alan F. Schatzberg, MD) of the *Textbook of Psychopharmacology*, published by the APA Press and now in its fifth edition; is co-editor in chief of a new text book *Post-Traumatic Stress Disorder*, and is the co-editor in chief of a new journal published by Elsevier: *Personalized Medicine in Psychiatry*.

He received his MD and PhD (Neurobiology) degrees at the University of North Carolina (UNC) School of Medicine. After psychiatry residency training at UNC and Duke University, he held faculty positions at Duke and at Emory University before relocating to the University of Miami in 2009.

### **C. Neill Epperson, MD**

Dr. Epperson is the Robert Freedman Endowed Professor and Chair of the Department of Psychiatry at the University of Colorado School of Medicine-Anschutz Medical Campus (CU-AMC). Before being recruited to CU-AMC, Dr. Epperson served as the founder and director of both the Penn Center for Women's Behavioral Wellness and Penn PROMOTES, Research on Sex and Gender in Health at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia where she was a tenured Professor of Psychiatry, with a secondary appointment in Obstetrics and Gynecology. Dr. Epperson received her medical degree at The University of North Carolina at Chapel Hill and completed her postdoctoral and research training in psychiatry at Yale University School of Medicine, New Haven, Connecticut, where she rose to the level of associate professor before her recruitment to the University of Pennsylvania.

Dr. Epperson is internationally known for her unique lifespan approach to women's reproductive and behavioral health in both her clinical and research approaches. Her work related to early life stress and its impact on risk for affective disorders during periods of hormonal change, as well as projects relating to cognitive decline during menopause and sex differences among smokers have been funded by the National Cancer Institute, National Institute of Mental Health, the Office of Research on Women's Health, and the National Institute on Drug Abuse. Her body of work has led to a greater appreciation of the impact of childhood adversity on physiologic responses during times of hormonal fluctuation as well as gonadal steroid effects on brain and behavior. Dr. Epperson's research has been consistently funded by the National Institutes of Health for more than 2 decades. She is a productive mentor and independent investigator with more than 200 peer-reviewed publications and presentations.

### **Mark S. Gold, MD**

Dr. Gold is a teacher of the year, translational researcher, author, mentor, and inventor, best known for his work on the brain systems underlying the effects of opiate drugs, cocaine, and food. He has worked as an advisor to many White House Drug Czars, White House NIDA, and NIMH directors over his career of 40+ years. He is an author and inventor who has published over 1,000 peer-reviewed scientific articles, texts, and practice guidelines. This pioneering work started with detoxification studies using clonidine and lofexidine as a non-opiate detox followed by oral naltrexone at Yale in the late 70s and continued at the University of Florida (UF). Dr. Gold translated opioid studies using mouse, rat, and non-human primate models before developing his opioid withdrawal hypothesis with his Yale colleagues. He then led the first studies to demonstrate non-opioid treatment efficacy for alpha-2 agonists. He also led rapid detoxification and clonidine to naltrexone studies in the late 70s and early 80s. Dr. Gold, trying to find patients who would take oral naltrexone, began his studies of Impaired Health Professionals and employees in health and safety occupations.

# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

Dr. Gold has received a number of national awards for his research, including the Lifetime Achievement Award of the National Association of Addiction Treatment Professionals, Foundations Fund Prize (APA), PRIDE Lifetime Achievement Award, DEA 30 Years of Service Pin, the McGovern Award for Lifetime Achievement (ASAM-ABAM 2015), National Leadership Award (NAATP), DARE Lifetime Achievement Award, Public Relations Society's Silver Anvil Award, and China Academy of Sciences and DARE awards for his career in research and prevention (2015). More recently, he received the PATH Foundation's Lifetime Achievement Award (2016) as one of the "fathers" of addiction medicine, presented to him by President Obama's White House Drug Czar Michael Botticelli. Dr. Gold was awarded Distinguished Alumni Awards at Yale University, University of Florida, and Washington University in St. Louis as well as the Wall of Fame at the UF College of Medicine.

Dr. Gold was a Professor, Eminent Scholar, Distinguished Professor, Distinguished Alumni Professor, Chairman, and Emeritus Eminent Scholar during his 25 years at the University of Florida. His work is widely cited by his peers. It includes citation classics in cocaine neurobiology, opioid addiction neurobiology and treatment, and food and process addictions. He proved that cocaine was misclassified as safe, or the champagne of drugs, leading to revision in the DSM 3 and diagnosis of addiction. He has been called a groundbreaking researcher, father of medication-assisted recovery, the first to translate rat experiments into theory and treatments for human addicts, and mentor of the next generation of addiction researchers and clinicians. Working closely with Bart Hoebel at Princeton University, Dr. Gold helped develop the food addiction theory he posited in the 80s. With Nicole Avena, he worked on sugar self-administration models for hedonic overeating and developed new treatments for overeating and obesity. Kelly Brownell and Dr. Gold's *Food and Addiction*, published by Oxford University Press, has been widely recognized as groundbreaking. Although working on food and drug-like reinforcement systems has been an important part of his work for 30 years, he has also worked on dual disorders, anorexia, and bulimia nervosa. Dr. Gold worked closely with Al Rhoton and Bill Luttge to establish the UF Brain Institute. He was an original member of the McKnight Brain Institute and Director working to develop programs in Psychiatry, Addiction, Neurology, and Neurosurgery.

Since his retirement as a Director of the McKnight Brain Institute, Chairman, Distinguished Professor, and a full-time academic in 2014, Dr. Gold has continued his teaching, mentoring, research, and writing. He finished his 5-year State Department grant on opium smokers and the effects of second- and third-hand opium on children in Afghanistan. He has worked on de novo clinical addiction programs at the Medical College of Georgia, Northwestern, UF, and Tulane Lakeview Health. Dr. Gold regularly lectures at national and international meetings, medical societies, grand rounds around the United States, and international and national scientific meetings on his career, bench-to-bedside science in eating disorders, obesity, and addictions. Recently, he gave a keynote speech at the National Opioid Summit and Florida Opioid Summit as well as for the DEA-DOJ. He speaks regularly at medical schools across the United States, recently at Yale University, Mayo Clinic, Tulane, Washington University in St. Louis, Stanford, University of Connecticut (UConn), UCSF, Emory, Harvard-McLean-Borden Cottage, and UNC. He has given recent keynote addresses at American College of Psychiatrists, CADCA, ASAM, NAATP, APA, and Biological Psychiatry as well as at many states, medical, and psychiatric associations, dealing with the opioid epidemic.

Dr. Gold is an Adjunct Professor in the Department of Psychiatry at Washington University and an active member of the Clinical Council at the Washington University School of Medicine's Public Health Institute. He has Washington University mentees and works with them regularly. He is the Director of Research for the DEA Educational Association, working closely with the DEA and moderating their quarterly educational events broadcast from DEA Headquarters around the world.

## Ned H. Kalin, MD

Dr. Kalin is Hedberg Professor and Chairman of the Department of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is the Director of the HealthEmotions Research Institute and the Lane Neuroimaging Laboratory, a Professor in the Department of Psychology at the University of Wisconsin, and an affiliate scientist at the Wisconsin Regional Primate Center and the Harlow Primate Laboratory. He serves as the principal investigator for several ongoing NIH-funded research projects and has published over 250 peer-reviewed articles related to the adaptive and maladaptive expression of emotion and anxiety, and the childhood risk to develop anxiety disorders and depression. His research focuses on uncovering basic mechanisms that relate stress to the development of psychopathology and to understanding the mechanisms that cause some children to be vulnerable for the development of anxiety and depression. In addition to his research activities, he treats patients who suffer from anxiety and depression who are refractory to standard treatment.

Dr. Kalin earned his medical degree from Jefferson Medical School in Philadelphia, Pennsylvania, did his residency in the Department of Psychiatry at the University of Wisconsin, and did a fellowship in Neuropsychopharmacology at the National Institute of Mental Health. Dr. Kalin is board certified by the American Board of Psychiatry and

Neurology. He is a Fellow Emeritus of the American College of Neuropsychopharmacology and a fellow of the American College of Psychiatry. He has been recognized for numerous awards including the 1985 A.E. Bennett Award for basic science research in biological psychiatry, the 2005 Edward A. Strecker Award, the 2007 American College of Psychiatrists Award for research in mood disorders, the 2007 Gerald Klerman Senior Investigator Award, and the 2015 Anna-Monika Prize of the European College of Neuropsychopharmacology. In 2013 he was inducted as a Fellow in the American Association for the Advancement of Science, and in 2015 he was elected as a member of the National Academy of Medicine. In 2017, Dr. Kalin was inducted as a Distinguished Life Fellow of the American Psychiatric Association. He has served as President of the International Society of Psychoneuroendocrinology and President of the Society of Biological Psychiatry, as a member of the National Advisory Mental Health Council, and as Co-Editor for the international journal, *Psychoneuroendocrinology*. In 2019, Dr. Kalin was appointed as the Editor-in-Chief of the *American Journal of Psychiatry*.

### **Fred D. Lublin, MD**

Dr Lublin, MD is the Saunders Family Professor of Neurology at The Icahn School of Medicine at Mount Sinai and Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at that institution.

Dr. Lublin received his medical degree in 1972 from Jefferson Medical College, Philadelphia, PA. He completed his internship in Internal Medicine from the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.

As a neuroimmunologist, Dr. Lublin has a special interest in immune functions and abnormalities affecting the nervous system. He has been involved in both basic science and clinical research. He and his colleagues were among the first in the country involved with studies of Interferon beta-1b, which was approved by the Food & Drug Administration in 1993 to treat the relapsing-remitting form of Multiple Sclerosis. He is currently involved with several new clinical research protocols on promising agents for treating various aspects of MS. He was chairman of the National MS Society (USA) advisory committee on clinical trials of new drugs in Multiple Sclerosis and the National Multiple Sclerosis Society's Research Programs Advisory Committee. He was a member of the National MS Society National Board of Directors. He is past Chair of the New York City/Southern New York Chapter of NMSS Clinical Advisory Committee. He is a member of the International Medical & Scientific Board of the Multiple Sclerosis International Federation. Dr. Lublin and his colleagues at the National MS Society have re-defined the clinical course definitions of MS, updated in 2014. He has chaired a task force on the ethics of placebo-controlled trials in MS. Dr. Lublin is a member of the international panel that periodically redefines the diagnostic criteria for MS (McDonald Criteria). Dr. Lublin is co-chair of the National Institute of Neurological Diseases and Stroke MS Common Data Element committee and a member of their steering committee. He is a member of the WHO Advisory Group for the Revision of ICD-10 Diseases of the Nervous System working group on demyelinating diseases of the central nervous system. He was a Co-Chief and founding Editor of the journal *Multiple Sclerosis and Related Disorders*.

Dr. Lublin has published numerous scientific articles and is a member of many professional societies and advisory boards. Dr. Lublin has served as a consultant to the National Institutes of Health and to many pharmaceutical/biotech companies in all phases of new drug development and in preparation for presentation to the FDA and their advisory panels. He was the Principal Investigator of the NIH-sponsored multicenter Combination Therapy study in Multiple Sclerosis. In June of 2019, Dr. Lublin was awarded the June Halper Lifetime Achievement Award from the Consortium of Multiple Sclerosis Centers.

### **Charles R. Marmar, MD**

Dr. Marmar is the Lucius N. Littauer Professor and Chair of the Department of Psychiatry, NYU Langone Health (NYULH), and the Director of the Center for Alcohol Use Disorder and PTSD. Previously, Dr. Marmar was Professor & Vice Chair of the Department of Psychiatry at UCSF, & Associate Chief of Staff for Mental Health & Director of the PTSD Research Program at the San Francisco VA Medical Center. Dr. Marmar graduated from the University of Manitoba with a BSc in 1966 and an MD in 1970, and did his residency in Psychiatry at the University of Toronto in 1976 and a psychiatry fellowship at the University of San Francisco in 1978.

Internationally renowned for his expertise in PTSD for over 25 years, his focus ranges from combat-related conditions in veterans, including Iraq and Afghanistan vets, to PTSD in refugees and earthquake victims. He has served on multiple committees and scientific advisory groups at the national level for both the VA and the National Institute of Mental Health (NIMH) and as counsel to the VA Medical Centers, fire departments, disaster response teams, and police department including the NYPD. An award-winning teacher and researcher, Dr. Marmar is currently the principal investigator of numerous PTSD-related grants funded by the Department of Defense and private philanthropic organizations. He conducts studies in psychopharmacology, psychopathology, psychobiology, quality of care, psychotherapy treatment, and phenomenology of PTSD. He has served as president of several international societies, has published extensively, and is on the editorial board of several publications.

# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

## W. Vaughn McCall, MD, MS

Dr. McCall has been the Case Distinguished University Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia (MCG) at Augusta University since 2012. He also serves as Executive Vice Dean of MCG. He completed his medical degree and post-graduate psychiatric training at Duke University. He completed a Masters degree in Epidemiology from Wake Forest University. He is board certified in general psychiatry, geriatric psychiatry, and sleep medicine. His research interests include depression, electroconvulsive therapy, quality of life, insomnia, and suicide. He received 22 years of research support from the National Institute of Mental Health, and he has 500 citations, including more than 210 peer-reviewed journal articles, with an H-index of 40. He is Editor of the *Journal of ECT*, Past Associate Editor for the *Journal of Clinical Sleep Medicine*, and on the Editorial Board of *Sleep*. He has been the Past President of the Association for Convulsive Therapy, and a prior Director of the Board of the American Academy of Sleep Medicine. He previously was the Chair of Psychiatry and Behavioral Medicine at Wake Forest University School of Medicine from 2001-2012.

## David Paydarfar, MD

Dr. Paydarfar is professor and the inaugural chair of the Department of Neurology at Dell Medical School. He previously served as professor and executive vice chair of the Department of Neurology at the University of Massachusetts Medical School, and as an associate faculty member of the Wyss Institute for Biologically Inspired Engineering at Harvard University. Dr. Paydarfar received a BS in physics (*summa cum laude*) from Duke University and an MD degree from The University of North Carolina at Chapel Hill. He completed his residency training in neurology at Massachusetts General Hospital and Harvard Medical School. He practices general neurology and is a fellow of the American Neurological Association and an investigator of the Clayton Foundation for Research.

Dr. Paydarfar's clinical research program seeks to develop novel biosensors, signal-processing algorithms, and user interfaces that will enable clinicians and researchers to track and predict the health of individual patients as well as entire populations. This approach will extend beyond current reactive alarm systems, enabling doctors to forecast — and avert — adverse disease trajectories and to test the impact of such a strategy on health outcomes. This engineering and informatics platform should provide unprecedented opportunities to conduct fieldwork on human physiology and pathophysiology.

Dr. Paydarfar's basic research program seeks to understand mechanisms underlying disease states associated with abnormal behavior of neural oscillators such as apnea, circadian dysrhythmias, and epilepsy, as well as the coordination of pacemakers with other physiological and behavioral functions. His research is funded by the National Institutes of Health, the National Science Foundation, and the Clayton Foundation for Research.

## Steven Siegel, MD, PhD

Dr. Siegel is a practicing physician-scientist specializing in the treatment of schizophrenia and psychosis. He comes to USC after 20 years at the University of Pennsylvania, where he had active roles in research, teaching, and clinical care. Dr. Siegel received his MD and PhD in Neurobiology at the Mount Sinai School of Medicine in 1996 after completing an undergraduate degree in Neuroscience at Colgate University in 1986. He later completed residency in Psychiatry and a Fellowship in Neuropsychiatry at the University of Pennsylvania before joining the faculty in 2001.

Dr. Siegel has made contributions to understanding the basic neurobiology of schizophrenia, autism, drug abuse, and nicotine dependence, as well as making significant contributions in the translation of his research to the bedside. His laboratory uses animal models to evaluate EEG and event-related brain activity, combined with behavioral and molecular studies. Additionally, his laboratory has established new methods for the treatment of schizophrenia by inventing long-acting biodegradable implants, now under development for clinical application. His work has been supported by federal, state, foundation, and industry sources over the past 20 years. He has published more than 130 manuscripts spanning topics related to drug abuse, basic research in animal models of schizophrenia and autism, as well as clinical aspects of schizophrenia. He is on the editorial board of several leading journals related to psychiatry and neurobiology.

## David M. Simpson, MD, FAAN

Dr. Simpson is Professor of Neurology at Icahn School of Medicine at Mount Sinai in New York, New York. He is also Director of the Clinical Neurophysiology Laboratories and Neuromuscular Division.

Dr. Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in Neurology at Cornell University Medical Center in New York. He had a fellowship in Clinical Neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.

Dr. Simpson is author of over 246 original peer-reviewed publications, 96 book chapters and, has edited 3 books, and serves on numerous editorial boards. He has been the principal investigator for numerous studies, including the treatment of neuropathic pain in patients with peripheral neuropathy, neurological complications of HIV/AIDS and treatment of spasticity, limb dystonia and tremor with botulinum toxin. He is Chair of the American Academy of Neurology's Subcommittee charged with generating evidence-based guidelines for the use of botulinum toxin. Dr. Simpson is a member of the American Neurological Association and the American Pain Society, Fellow of the American Academy of Neurology and the American Academy of Neuromuscular and Electrodiagnostic Medicine and President-Elect of the International Neurotoxin Association. He has received the Mitchell B Max Award for Neuropathic Pain from the American Academy of Neurology in 2018, granted for outstanding achievements in the field of neuropathic pain.

### **Charles F. Zorumski, MD**

Dr. Zorumski is the Samuel B. Guze (Goo-ZAY) Professor and Head of the Department of Psychiatry and Professor of Neuroscience at Washington University School of Medicine (WUSM) in St. Louis. Dr. Zorumski is also Psychiatrist-in-Chief at Barnes-Jewish Hospital and Director of the Taylor Family Institute for Innovative Psychiatric Research. Dr. Zorumski's laboratory studies synaptic transmission in the hippocampus. His studies focus on short- and long-term modulation of the glutamate and GABA neurotransmitter systems, with emphasis on how these transmitter systems participate in memory and neuropsychiatric disorders. A long-standing interest concerns the mechanisms by which neurosteroids and oxysterols modulate GABA and glutamate receptors. Clinically, Dr. Zorumski is interested in the treatment of refractory mood disorders. He has published more than 340 scientific papers and five books, and holds five patents. His work has been funded by the National Institutes of Health since 1987.

Dr. Zorumski was named Head of the Washington University Department of Psychiatry in 1997 and Samuel B. Guze Professor in 1998. Since 1997, he has served on the Steering Committees of the McDonnell Center for Cellular and Molecular Neurobiology and the McDonnell Center for Systems Neuroscience and was Director of the Center for Cellular and Molecular Neurobiology from 2002 to 2013. Dr. Zorumski was named founding Director of the Taylor Family Institute in 2012. In 2015, Dr. Zorumski became Chair of the Center for Brain Research in Mood Disorders. He serves on the Editorial Boards of *JAMA Psychiatry* and *Cerebrum* and served on the Board of Scientific Counselors for the NIMH Intramural Research Program from 2009 to 2013. Dr. Zorumski is a distinguished fellow of the American Psychiatric Association, and a fellow of the American College of Neuropsychopharmacology and the American Psychopathological Association. He was elected to the National Academy of Medicine (Institute of Medicine) in 2012 and has previously served on the Academy's Forum on Neuroscience and Nervous System Disorders. Since 2011, he has also served on the Scientific Advisory Board of Sage Therapeutics, a publicly traded company developing neurosteroids and oxysterols as treatments for neuropsychiatric illnesses.



## DISCLOSURE AND CONFLICT OF INTEREST RESOLUTION

All conflicts of interest of any individual(s) in a position to control the content of this CME activity will be identified and resolved prior to this educational activity being provided. Disclosure about provider and faculty relationships, or the lack thereof, will be provided to the learners.

## DISCLOSURE DECLARATION

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporters of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

CME Outfitters, LLC, and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Dr. Nemeroff has disclosed that he receives grants/research support from National Institutes of Health (NIH). He is a consultant for ACADIA Pharmaceuticals Inc.; Bracket (Clintara); EMA Wellness; Gerson Lehrman Group, Inc. (GLG); Intra-Cellular Therapies, Inc.; Janssen Research & Development LLC; Magstim, Inc.; Navitor Pharmaceuticals, Inc.; Sunovion Pharmaceuticals Inc.; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; TC MSO, Inc.; and Xhale, Inc. He is a stock shareholder of AbbVie Inc.; Antares Pharma; BI Gen Holdings, Inc.; Celgene Corporation; Corcept Therapeutics; EMA Wellness; OPKO Health Inc.; Seattle Genetics, Inc.; TC MSO, Inc.; Trends in Pharma Development, LLC; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); Bracket (Clintara); Brain & Behavior Research Foundation (BBRF); Laureate Institute for Brain Research, Inc.; Skyland Trail; and Xhale, Inc. He serves on the board of directors for the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; and Xhale, Inc. He receives income sources or equity of \$10,000 or more from American Psychiatric Publishing; Bracket (Clintara); CME Outfitters, LLC; EMA Wellness; Intra-Cellular Therapies, Inc.; Magstim, Inc.; and Xhale, Inc. He holds the following patents: Method and devices for transdermal delivery of lithium (US 6,375,990B1); Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2); Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8,511,996B2).

Dr. Epperson has disclosed that she receives grants and research support from Sage Therapeutics. She is on the speakers bureau of Sage Therapeutics. She serves as a consultant to Asarina Pharma; and Sage Therapeutics. She is on the advisory board of Asarina Pharma.

Dr. Gold has disclosed that he serves as a consultant for ADAPT Pharma (Dublin, Ireland).

Dr. Kalin has disclosed that he receives grant and research support from National Institutes of Health (NIH), Principal Investigator and National Institute of Mental Health (NIMH), and Principal Investigator. He is a consultant for American Psychiatric Association; Editorial Services for the *American Journal of Psychiatry*. He is on the Advisory Committee for Pritzker Neuropsychiatric Disorders Research Consortium and Skyland Trail Advisory Board. He receives other financial or material support from the American Psychiatric Association; Editor of the *American Journal of Psychiatry*.

Dr. Lublin has disclosed that he serves as a consultant for Acorda Therapeutics; Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; Celgene Corporation; EMD Serono, Inc.; Forward Pharma; Genentech, Inc.; Genzyme Corporation; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma; Receptos, Inc.; Regeneron; Roche; Sanofi; Teva Pharmaceuticals; and TG Therapeutics, Inc. He is on the speaker's bureau of Sanofi.

Dr. Marmar has disclosed that he receives research and clinical program funding (current and past 10 years) from Bank of America Foundation; Brockman Foundation; City of New York; Cohen Veterans Bioscience (CVB); Cohen Veterans Network (CVN); Home Depot Foundation; McCormick Foundation; National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institute of Mental Health (NIMH); Northern California Institute for Research and Education (NCIRE); Robin Hood Foundation; Steven & Alexandra Cohen Foundation; Tilray; U.S. Army Medical Research & Acquisition Activity (USAMRA); U.S. Army Telemedicine & Advanced Technology Research Center (TATRC); and U.S. Department of Defense (DoD). He served as a PTSD Fellow for the George W. Bush Institute. He serves on the scientific advisory board and has equity in Receptor Life Sciences.

Dr. McCall has disclosed that he receives grant and research support from MECTA Corporation; Merck & Co., Inc.; and VistaGen Therapeutics, Inc. He serves on the advisory committee of and is a consultant to Jazz Pharmaceuticals, Inc; and Sage Therapeutics, Inc. He receives royalties from Wolters Kluwer Publishing.

Dr. Paydarfar has disclosed that he receives grants and research support from Clayton Foundation; Merck & Co., Inc.; National Institutes of Health (NIH); National Science Foundation (NSF); and Texas Alzheimer's Research and Care Consortium. He is on the advisory committee for Prapela, Inc.

Dr. Siegel has disclosed that he receives grant support from Astellas Research Institute of America LLC. He serves as a consultant to Zynerba Pharmaceuticals, Inc.

Dr. Simpson has disclosed that he receives grants and research support from, on the advisory committee of, serves as a consultant to, and on the speakers bureau of Allergan; Ipsen Biopharmaceuticals, Inc.; Merz Pharma; and Revance Therapeutics, Inc.

Dr. Zorumski has disclosed that he receives grants from Bantky Foundation; National Institute of Mental Health (NIMH); and Sage Therapeutics. He is a consultant for Sage Therapeutics, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a stock shareholder (directly purchased) of Sage Therapeutics, Inc. He holds patents to Neurosteroid analogs and GABA receptors; redox reagents and T-channels; and oxysterols as neuroprotectants.

Howard Bliwise, MD (peer reviewer) has no disclosures to report.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Olga Askinazi (planning committee) has no disclosures to report.

Evan Luburger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

# 12TH ANNUAL CHAIR SUMMIT



Master Class for Neuroscience Professional Development

## CHAIR SUMMIT TWITTER GUIDE



Welcome to the 12th Annual Chair Summit and thank you for your interest in participating in the **#Chair2020** Twitter conversation! If you do not have a Twitter account, please begin at step #1. If you already have your account set up, please begin at step #5.

1. Go to [www.twitter.com](http://www.twitter.com) and click **“Sign up for Twitter”**
2. Fill in your information and click **“Create my account”**
3. Once your account is created, Twitter will take you through a quick tutorial to help you get started.  
*Twitter will prompt you to select people/associations to follow. Please follow CME Outfitters. If you enter search terms such as neurology, psychiatry, CME, Alzheimer’s, etc., Twitter will find people/organizations associated with those terms for you to follow. You can also choose to skip steps for now to speed up the process.*
4. After you complete the set-up process, Twitter will direct you to your home screen where you will see a tweet stream along the right side of the screen, and a text box on the left side of the screen that reads “Compose new Tweet....” This text box is where you will enter your tweets.
5. In the search box at the top of the screen, enter: **#Chair2020**
6. You will see the **#Chair2020** tweet stream appear. Under **“Results for #Chair2020”** please select **“All”** so that you can view all tweets related to Chair.
7. **Please follow the #Chair2020 tweet stream during the conference**, and reply, retweet, or compose your own tweets using hashtag #Chair2020. You may tweet questions for faculty presenters, comments on the sessions, links to educational resources, thoughts, notes, and more! However please remember to include #Chair2020 at the end of every tweet so that your tweets appear in the conference tweet stream.
8. If you get stuck, or have questions about Twitter during the meeting, you can ask your questions to CMEO’s Social Media Manager, Anna Larkin, at the registration desk or email her at [alarkin@cmeoutfitters.com](mailto:alarkin@cmeoutfitters.com).

The purpose of the Twitter feature at Chair Summit is to allow you the opportunity to interact with your peers and the Chairmen LIVE as the conference is happening. CME Outfitters is committed to providing you with opportunities to utilize the latest social technological advances so that you can be engaged in the meeting every step of the way, and make the absolute most of your experience with us. So jump right in ... and have fun with it!

# #CHAIR2020















**HOTEL FLOOR PLAN**  
 (Level 3)



**HOTEL FLOOR PLAN**  
 (Level 4)



**LOCATIONS AT-A-GLANCE**

**All Plenary Sessions:** Social A (3rd Floor)

**Exhibit / Meals:** Social B & C (3rd Floor)

Please check the agenda to find the correct location for the Breakout and Chart Review sessions of your choice. (3rd & 4th Floors)

**CBD 2020**  A Special  
Pre-Conference  
Event  
**CONFERENCE**  
Exploring the Evidence for Medical Cannabis in Clinical Practice

**12TH ANNUAL**   
**CHAIR SUMMIT**  
Master Class for Neuroscience Professional Development



[www.ChairSummit.com](http://www.ChairSummit.com)